RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM

SamuelZ Goldhaber, John Heit, G. V R K Sharma, J. Stevan Nagel, Ducksoo Kim, J. Anthony Parker, David Drum, Kathleen Reagan, James Anderson, CraigM Kessler, John Markis, Douglas Dawley, Michael Meyerovitz, DouglasE Vaughan, SabahS Tumeh, Joseph Loscalzo, AndrewP Selwyn, Eugene Braunwald

Research output: Contribution to journalArticle

268 Citations (Scopus)

Abstract

The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82% of rt-PA-treated patients showed clot lysis, compared with 48% of urokinase-treated patients (p=0·008; 95% CI for the difference = 10-58%). Improvement in lung scan reperfusion at 24 h was identical in the two treatment groups. The reduction in fibrinogen did not differ significantly between the rt-PA and urokinase groups (45% vs 39% at 2 h and 34% vs 40% at 24 h). The results indicate that in the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE.

Original languageEnglish (US)
Pages (from-to)293-298
Number of pages6
JournalThe Lancet
Volume332
Issue number8606
DOIs
StatePublished - Aug 6 1988

Fingerprint

Urokinase-Type Plasminogen Activator
Tissue Plasminogen Activator
Pulmonary Embolism
Randomized Controlled Trials
Lung
Reperfusion
Therapeutics
Fibrinogen
Angiography
Hypersensitivity
Perfusion
Hemorrhage

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Goldhaber, S., Heit, J., Sharma, G. V. R. K., Nagel, J. S., Kim, D., Parker, J. A., ... Braunwald, E. (1988). RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM. The Lancet, 332(8606), 293-298. https://doi.org/10.1016/S0140-6736(88)92354-9

RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM. / Goldhaber, SamuelZ; Heit, John; Sharma, G. V R K; Nagel, J. Stevan; Kim, Ducksoo; Parker, J. Anthony; Drum, David; Reagan, Kathleen; Anderson, James; Kessler, CraigM; Markis, John; Dawley, Douglas; Meyerovitz, Michael; Vaughan, DouglasE; Tumeh, SabahS; Loscalzo, Joseph; Selwyn, AndrewP; Braunwald, Eugene.

In: The Lancet, Vol. 332, No. 8606, 06.08.1988, p. 293-298.

Research output: Contribution to journalArticle

Goldhaber, S, Heit, J, Sharma, GVRK, Nagel, JS, Kim, D, Parker, JA, Drum, D, Reagan, K, Anderson, J, Kessler, C, Markis, J, Dawley, D, Meyerovitz, M, Vaughan, D, Tumeh, S, Loscalzo, J, Selwyn, A & Braunwald, E 1988, 'RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM', The Lancet, vol. 332, no. 8606, pp. 293-298. https://doi.org/10.1016/S0140-6736(88)92354-9
Goldhaber, SamuelZ ; Heit, John ; Sharma, G. V R K ; Nagel, J. Stevan ; Kim, Ducksoo ; Parker, J. Anthony ; Drum, David ; Reagan, Kathleen ; Anderson, James ; Kessler, CraigM ; Markis, John ; Dawley, Douglas ; Meyerovitz, Michael ; Vaughan, DouglasE ; Tumeh, SabahS ; Loscalzo, Joseph ; Selwyn, AndrewP ; Braunwald, Eugene. / RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM. In: The Lancet. 1988 ; Vol. 332, No. 8606. pp. 293-298.
@article{61588fe7cc06408fbf134c14d601f72d,
title = "RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM",
abstract = "The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82{\%} of rt-PA-treated patients showed clot lysis, compared with 48{\%} of urokinase-treated patients (p=0·008; 95{\%} CI for the difference = 10-58{\%}). Improvement in lung scan reperfusion at 24 h was identical in the two treatment groups. The reduction in fibrinogen did not differ significantly between the rt-PA and urokinase groups (45{\%} vs 39{\%} at 2 h and 34{\%} vs 40{\%} at 24 h). The results indicate that in the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE.",
author = "SamuelZ Goldhaber and John Heit and Sharma, {G. V R K} and Nagel, {J. Stevan} and Ducksoo Kim and Parker, {J. Anthony} and David Drum and Kathleen Reagan and James Anderson and CraigM Kessler and John Markis and Douglas Dawley and Michael Meyerovitz and DouglasE Vaughan and SabahS Tumeh and Joseph Loscalzo and AndrewP Selwyn and Eugene Braunwald",
year = "1988",
month = "8",
day = "6",
doi = "10.1016/S0140-6736(88)92354-9",
language = "English (US)",
volume = "332",
pages = "293--298",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8606",

}

TY - JOUR

T1 - RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM

AU - Goldhaber, SamuelZ

AU - Heit, John

AU - Sharma, G. V R K

AU - Nagel, J. Stevan

AU - Kim, Ducksoo

AU - Parker, J. Anthony

AU - Drum, David

AU - Reagan, Kathleen

AU - Anderson, James

AU - Kessler, CraigM

AU - Markis, John

AU - Dawley, Douglas

AU - Meyerovitz, Michael

AU - Vaughan, DouglasE

AU - Tumeh, SabahS

AU - Loscalzo, Joseph

AU - Selwyn, AndrewP

AU - Braunwald, Eugene

PY - 1988/8/6

Y1 - 1988/8/6

N2 - The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82% of rt-PA-treated patients showed clot lysis, compared with 48% of urokinase-treated patients (p=0·008; 95% CI for the difference = 10-58%). Improvement in lung scan reperfusion at 24 h was identical in the two treatment groups. The reduction in fibrinogen did not differ significantly between the rt-PA and urokinase groups (45% vs 39% at 2 h and 34% vs 40% at 24 h). The results indicate that in the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE.

AB - The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82% of rt-PA-treated patients showed clot lysis, compared with 48% of urokinase-treated patients (p=0·008; 95% CI for the difference = 10-58%). Improvement in lung scan reperfusion at 24 h was identical in the two treatment groups. The reduction in fibrinogen did not differ significantly between the rt-PA and urokinase groups (45% vs 39% at 2 h and 34% vs 40% at 24 h). The results indicate that in the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE.

UR - http://www.scopus.com/inward/record.url?scp=0023752733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023752733&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(88)92354-9

DO - 10.1016/S0140-6736(88)92354-9

M3 - Article

C2 - 2899718

AN - SCOPUS:0023752733

VL - 332

SP - 293

EP - 298

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8606

ER -